

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: :  
: :  
Naganori Numao : :  
Serial No.: To be assigned : Art Unit: To be assigned  
: :  
Filed: Herewith : Examiner: To be assigned  
: :  
For: PREDICTION OF : Atty Docket: 21776/0061  
UNKNOWN BIOLOGICAL :  
FUNCTION OF THE :  
ACTIVE SITE IN PROTEINS :  
OR/AND :  
POLYNUCLEOTIDES, AND :  
ITS UTILIZATION :



INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
Washington, D.C. 20231

Sir:

For ensuring compliance with the applicant's duty of disclosure under 37 CFR § 1.56, the undersigned hereby submits the documents listed on the attached Form PTO-1449 for consideration by the Examiner in charge of the above-identified patent application.

The listing of these materials is not to be construed as an admission that such is actually prior art with respect to the invention of the present application and is not to be construed that such is material with respect to the present invention.

These documents are being submitted (check only one of the next four boxes):

☒ [XXX] within three months of the filing of the above U.S. national application or of the date of entry of the U.S. national stage in an International Patent Application (no fee is due);

☐ [ ] before receiving a first Office Action on the merits of the above-identified patent application (no fee is due);

- ☐ following receipt of a first Office Action, but before issuance of a Final Office Action or a Notice of Allowance (if this box is checked, the fee box below OR one of the last two boxes must be checked);

OR

- ☐ following receipt of a Notice of Allowance or a Final Office Action (if this box is checked, the next box and one of the last two boxes also must be checked).

FEE

- ☐ The Director is hereby authorized to charge the \$180.00 fee set forth in 37 CFR § 1.17(p) to Deposit Account No. 22-0185.

CERTIFICATION

- ☐ The undersigned certifies that each item of this information is being submitted within three months of the date it was first cited in any communication from a foreign patent office in a counterpart foreign application.
- ☐ The undersigned certifies that no item of information contained in the information disclosure statement was first cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this information disclosure statement.

The Director is hereby authorized to charge payment of any deficiency in the above fee(s) or to charge any additional fees required under 37 CFR § 1.16 or 1.17 or credit any overpayment to Deposit Account No. 22-0185. A duplicate copy of this authorization is attached for the Finance Branch.

Respectfully submitted,




George R. Pettit, Reg. No. 27,369  
Connolly Bove Lodge & Hutz LLP  
1990 M Street, N.W.  
Washington, D.C. 20036-3425  
Telephone: 202-331-7111

Date: 12/27/01

FORM PTO-1449  <b>INFORMATION DISCLOSURE CITATION</b>	Atty Docket 21776/0066	Serial No. To be assigned
	Applicant Naganori Numao	
	Filing Date Herewith	Group Art Unit To be assigned

## U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Sub-Class	Filing Date
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						



## FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Sub-Class	Translation
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR		Ogawa, N., et al., "New Components of a System for Phosphate Accumulation and Polyphosphate Metabolism in <i>Saccharomyces cerevisiae</i> Revealed by Genomic Expression Analysis," <i>Molecular Biology of the Cell</i> , Vol. 11, pp. 4309-4321, December 2000
	AS		Shigekazu Nagata, "Apoptosis by Death Factor," <i>Cell</i> , Vol. 88, pp. 355-365, 1997
	AT		

Examiner	Date Considered
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP § 600. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant(s).